Handel Immunovant Inc - IMVT CFD

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Najnowsze artykuły o akcjach

Chcesz dołączyć do wiodącego brokera?

Dołącz do naszej społeczności inwestorów na całym świecie
1. Utwórz swoje konto2. Dokonaj swojej pierwszej wpłaty3. Rozpocznij handlowanie